BiotechTube
Buzzard Pharmaceutical

Buzzard Pharmaceutical

Stockholm, Sweden· Est.
buzzardpharma.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Buzzard Pharmaceuticals is a Swedish biotech advancing isunakinra, a potent dual IL-1α/IL-1β inhibitor, for cancer. The company is building on promising Phase I data and is currently running a Phase 2A study in microsatellite stable, KRAS-mutated colorectal cancer, with plans to initiate a trial in neoadjuvant triple-negative breast cancer. Its strategy leverages the role of IL-1 as a master regulator of tumor-promoting inflammation and immunosuppression, aiming to enhance the efficacy of existing immunotherapies like PD-1 inhibitors.

Oncology

Technology Platform

Next-generation IL-1 inhibition platform targeting the IL-1 receptor type 1 (IL-1R1) to potently block both IL-1α and IL-1β, aiming to reprogram the immunosuppressive tumor microenvironment and synergize with checkpoint inhibitors.

Opportunities

The significant unmet need in immunotherapy-resistant cancers like MSS-CRC and TNBC presents a major opportunity.
Demonstrating clinical proof-of-concept could position Buzzard as an attractive partner for larger oncology companies seeking novel combination therapies.
The broader applicability of IL-1 inhibition across multiple inflammation-driven cancers offers substantial pipeline expansion potential.

Risk Factors

High clinical development risk in difficult-to-treat cancer indications where many therapies have failed.
Heavy reliance on a single asset, isunakinra, creates concentration risk.
As a private, pre-revenue company, it faces ongoing financing risks and potential dilution to continue funding trials.

Competitive Landscape

The IL-1 space in oncology has historical players like Novartis (canakinumab) but is not yet crowded. Buzzard competes with other companies developing TME-modulating agents and combination immuno-therapies. Its differentiation lies in the specific potency and design of isunakinra and its focused strategy on defined, biomarker-selected patient populations like KRAS-mutant MSS-CRC.

More companies in Sweden →